BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 14695159)

  • 1. Improvement of the antitumor activity of intraperitoneally and orally administered 5,6-dimethylxanthenone-4-acetic acid by optimal scheduling.
    Zhao L; Ching LM; Kestell P; Baguley BC
    Clin Cancer Res; 2003 Dec; 9(17):6545-50. PubMed ID: 14695159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy.
    Seshadri M; Spernyak JA; Mazurchuk R; Camacho SH; Oseroff AR; Cheney RT; Bellnier DA
    Clin Cancer Res; 2005 Jun; 11(11):4241-50. PubMed ID: 15930363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors.
    Bellnier DA; Gollnick SO; Camacho SH; Greco WR; Cheney RT
    Cancer Res; 2003 Nov; 63(22):7584-90. PubMed ID: 14633671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects.
    Baguley BC; Zhuang L; Kestell P
    Oncol Res; 1997; 9(2):55-60. PubMed ID: 9167186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide.
    Chung F; Liu J; Ching LM; Baguley BC
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):497-502. PubMed ID: 17473922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor dose response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy.
    McPhail LD; Chung YL; Madhu B; Clark S; Griffiths JR; Kelland LR; Robinson SP
    Clin Cancer Res; 2005 May; 11(10):3705-13. PubMed ID: 15897567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid.
    Cao Z; Joseph WR; Browne WL; Mountjoy KG; Palmer BD; Baguley BC; Ching LM
    Br J Cancer; 1999 May; 80(5-6):716-23. PubMed ID: 10360649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo.
    O'Dwyer PJ; Moyer JD; Suffness M; Harrison SD; Cysyk R; Hamilton TC; Plowman J
    Cancer Res; 1994 Feb; 54(3):724-9. PubMed ID: 8306334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy.
    Joseph WR; Cao Z; Mountjoy KG; Marshall ES; Baguley BC; Ching LM
    Cancer Res; 1999 Feb; 59(3):633-8. PubMed ID: 9973211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor.
    Chung F; Wang LC; Kestell P; Baguley BC; Ching LM
    Cancer Chemother Pharmacol; 2004 May; 53(5):377-83. PubMed ID: 15060740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial.
    Jameson MB; Baguley BC; Kestell P; Zhao L; Paxton JW; Thompson PI; Waller S;
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):681-7. PubMed ID: 17021822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo.
    McKeage MJ; Kelland LR; Boxall FE; Valenti MR; Jones M; Goddard PM; Gwynne J; Harrap KR
    Cancer Res; 1994 Aug; 54(15):4118-22. PubMed ID: 8033145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
    Peterson JK; Tucker C; Favours E; Cheshire PJ; Creech J; Billups CA; Smykla R; Lee FY; Houghton PJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6950-8. PubMed ID: 16203787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent.
    McKeage MJ; Fong P; Jeffery M; Baguley BC; Kestell P; Ravic M; Jameson MB
    Clin Cancer Res; 2006 Mar; 12(6):1776-84. PubMed ID: 16551862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice.
    Ching LM; Goldsmith D; Joseph WR; Körner H; Sedgwick JD; Baguley BC
    Cancer Res; 1999 Jul; 59(14):3304-7. PubMed ID: 10416582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients.
    Li J; Jameson MB; Baguley BC; Pili R; Baker SD
    Clin Cancer Res; 2008 Apr; 14(7):2102-10. PubMed ID: 18381951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
    Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
    Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical evaluation of the anticancer activity and toxicity of 9-nitro-20(S)-camptothecin (Rubitecan).
    Giovanella BC; Stehlin JS; Hinz HR; Kozielski AJ; Harris NJ; Vardeman DM
    Int J Oncol; 2002 Jan; 20(1):81-8. PubMed ID: 11743646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Zhou S; Kestell P; Tingle MD; Paxton JW
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):126-32. PubMed ID: 11862426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice.
    Zhao L; Kestell P; Ching LM; Baguley BC
    Cancer Chemother Pharmacol; 2002 Jan; 49(1):20-6. PubMed ID: 11855749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.